AstraZeneca Corp. - AZN Net earnings per share (EPS TTM)

Official company branding of AstraZeneca (AZN)

AstraZeneca PLC (AZN) is developing a high-tech treatment system for oncology and orphan diseases while facing pricing pressure from regulators. Manufacturing capacities are scaling through external contractors, necessitating rigorous quality control. Decarbonization and eco-friendly inhalers complement the ESG strategy. The company's net income per share over 12 months demonstrates financial resilience, where the value of 7.10 reflects this status.

AZN (AstraZeneca PLC) Net earnings per share for the last four quarters history from 07/04/2022 to 11/12/2026

Analytical breakdowns for AstraZeneca PLC

- current quotes and average value forecast:
Price Chart AstraZeneca PLC|AZN - Price Target Chart
- issuer market value details:
Market Capitalization AstraZeneca PLC|AZN - Business Value
- business book valuation details:
Book Value per Share AstraZeneca|AZN - Book Valuation of Business|Market Value to Book Value Ratio astrazeneca.com|AZN - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital AstraZeneca PLC|AZN - Long-Term Indebtedness to Equity|Short-Term Debt to Capital AstraZeneca AB|AZN - Company Aggregate Debts|Debt to Book Capitalization Ratio AstraZeneca PLC|AZN - Long-Term Debt Volume|Company Current Liabilities AstraZeneca|Quick Liquidity astrazeneca.com
- net income and valuation multiples indicators:
AZN - Final Profit|Projected Future Earnings AstraZeneca PLC|AZN - P/E Multiple|Projected Price to Earnings AstraZeneca|AZN - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple AstraZeneca PLC|AZN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months AstraZeneca|AZN - Earnings per share for the last 12 months|Quarterly EPS earnings growth astrazeneca.com|AZN - Earnings per share growth rate in current year|Earnings growth forecast for next year AstraZeneca PLC
Analysis of all company metrics:AZN - AstraZeneca PLC
Manufactured products of AstraZeneca Plc

For AstraZeneca PLC (AZN), whose returns rely on patent protection and the success of new oncology drugs, the rolling annual EPS chart reflects the actual efficiency of R&D investments. This indicator captures actual net income divided by the number of shares over the last 12 months, eliminating forecast subjectivity and smoothing reporting lags. This allows the investor to objectively assess the business trajectory and the asset's fundamental value.

Competitors of AstraZeneca PLC

LLY - Earnings per share for the last twelve months|ABBV: Earnings per share for the last twelve months|NVS: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months MRK|NVO (Novo Nordisk Inc.) - Net earnings per share (EPS TTM)|Amgen Inc (AMGN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pfizer Inc. (PFE)|sanofi.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) BMY (Bristol Myers Squibb)|Net earnings per share for the trailing year GlaxoSmithKline plc|Takeda Pharmaceutical Company Limited - Net earnings per share (EPS TTM)|TEVA - Net earnings per share (EPS TTM)|Dr. Reddy's Laboratories (RDY) - Earnings per share for the last twelve months|VTRS - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ROIV|ZLAB (Zai Lab Ltd) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Valeant Pharmaceuticals (BHC)|COSM (Cosmos Health Inc) - Earnings per share for the trailing year